Management of Venous Thromboembolism in Patients with Advanced Gastrointestinal Cancers: What Is the Role of Novel Oral Anticoagulants? | Zendy

Ludmila Katherine Martin | Zendy; Tanios BekaiiSaab | Zendy

Open Access

Management of Venous Thromboembolism in Patients with Advanced Gastrointestinal Cancers: What Is the Role of Novel Oral Anticoagulants?

Author(s) -

Ludmila Katherine Martin,

Tanios BekaiiSaab

Publication year - 2012

Publication title -

thrombosis

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.494

H-Index - 3

eISSN - 2090-1496

pISSN - 2090-1488

DOI - 10.1155/2012/758385

Subject(s) - medicine , rivaroxaban , apixaban , dabigatran , venous thromboembolism , intensive care medicine , gastrointestinal cancer , cancer , gastrointestinal bleeding , edoxaban , ambulatory , warfarin , colorectal cancer , atrial fibrillation , thrombosis

Venous thromboembolism (VTE) is a frequent complication of gastrointestinal cancers that increases morbidity and may impact mortality. Low-molecular-weight heparins (LMWHs) and vitamin K antagonists (VKAs) are standard anticoagulation options for the ambulatory gastrointestinal cancer patient with VTE, but both of these agents are challenging to use for various reasons. Novel oral anticoagulants (NOAs) are new, orally available anticoagulants designed to be easier to administer with more reliable pharmacokinetics that eliminate the need for frequent monitoring of various laboratory parameters. This paper reviews the existing efficacy and safety data for the use of NOAs dabigatran etexilate, rivaroxaban, and apixaban and discusses the potential role of these agents in the management of gastrointestinal cancer-related VTE.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research